# OnCo record neolap (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/neolap/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "neolap", "NCT02125136" ;
  schema:name "NEOLAP"@en ;
  schema:alternateName "NEOLAP-AIO-PAK-0113"@en, "AIO-PAK-0113"@en ;
  schema:description "NEOLAP asked whether switching to FOLFIRINOX after two months of gemcitabine and nab-paclitaxel converts more inoperable pancreatic cancers to operable ones; about a third to 44 percent were removed with either sequence and survival was similar, so both induction regimens are acceptable."@en ;
  schema:url <https://onco.cc/trials/neolap/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02125136>, <https://doi.org/10.1016/S2468-1253(20)30330-7> ;
  onco:status "negative" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/locally-advanced-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/folfirinox/> ;
  onco:companies <https://onco.cc/companies/aio/> ;
  onco:terms <https://onco.cc/terms/resectability/>, <https://onco.cc/terms/acute-cholangitis/> .